Pheton (NASDAQ:PTHL – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.
Insider & Institutional Ownership
7.5% of Aclarion shares are owned by institutional investors. 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Pheton and Aclarion”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pheton | $305,215.00 | 7.00 | -$660,000.00 | N/A | N/A |
| Aclarion | $80,000.00 | 86.40 | -$7.23 million | ($7.40) | -0.32 |
Pheton has higher revenue and earnings than Aclarion.
Risk and Volatility
Pheton has a beta of 5.4, suggesting that its stock price is 440% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Pheton and Aclarion, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pheton | 1 | 0 | 0 | 0 | 1.00 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
Aclarion has a consensus price target of $7.50, indicating a potential upside of 212.50%. Given Aclarion’s stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Pheton.
Profitability
This table compares Pheton and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pheton | N/A | N/A | N/A |
| Aclarion | -10,948.81% | -59.34% | -56.12% |
About Pheton
Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for Pheton Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pheton and related companies with MarketBeat.com's FREE daily email newsletter.
